A Decade of Clinical Advances in Chronic Rhinosinusitis: 2012–2022

Naclerio, Robert M.; Mullol, Joaquim; Stevens, Whitney W.

doi:10.1016/j.jaip.2022.10.030

Cited by 10 publications

(5 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent findings highlight the growing public health concern of AR, emphasizing the role of environmental exposures and lifestyle changes, especially during the COVID-19 pandemic [2]. Similarly, research on CRS reveals significant variations in prevalence and treatment trends worldwide, with substantial socioeconomic impacts in regions like the USA and Europe [3, 4]. However, limitations still persist in these studies, particularly regarding cohort sizes and the duration of follow-up periods, indicating a need for more comprehensive and long-term research in these fields.…”

Section: Introductionmentioning

confidence: 99%

National Trends in Allergic Rhinitis and Chronic Rhinosinusitis and COVID-19 Pandemic-Related Factors in South Korea, from 1998 to 2021

Lee,

Park,

Lee

et al. 2024

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Introduction: Existing studies provide insights into the prevalence and environmental factors associated with allergic rhinitis (AR) and chronic rhinosinusitis (CRS) globally. However, limitations still persist in these studies, particularly regarding cohort sizes and the duration of follow-up periods, indicating a need for more comprehensive and long-term research in these fields. Our study aimed to investigate the prevalence, long-term trends, and underlying factors of these conditions in the general population of adult participants (≥19 years) in Korea. Method: We analyzed data from adult participants (≥19 years) from the Korea National Health and Nutrition Examination Survey (KNHANES) study to determine the prevalence of AR and CRS from 1998 to 2021. To analyze prevalence trends before and during the COVID-19 pandemic, we employed a weighted linear regression model and obtained β-coefficients with 95% confidence intervals (CI). Results: Between 1998 and 2021, over a span of 24 years, the comprehensive KNHANES study included 146,264 adult participants (mean age: 47.80 years, standard deviation: 16.49 years; 66,177, 49.3% men). The prevalence of AR and CRS increased from 1998 to 2021, with AR prevalence rising from 5.84% (95% CI, 5.57–6.10) in 1998–2005 to 8.99% (8.09–9.91) in 2021 and CRS from 1.84% (1.70–1.97) in 1998–2005 to 3.70% (3.18–4.23) in 2021. However, the increasing trend has slowed down during the COVID-19 pandemic era. Conclusions: The significance of continuous monitoring and focused interventions for AR and CRS is underscored by this study. The observed deceleration in the rising prevalence of AR and CRS during the pandemic indicates the possibility of beneficial impacts from lifestyle modifications triggered by the pandemic. These findings call for additional research to explore potential protective effects in greater depth.

show abstract

Section: Introductionmentioning

confidence: 99%

National Trends in Allergic Rhinitis and Chronic Rhinosinusitis and COVID-19 Pandemic-Related Factors in South Korea, from 1998 to 2021

Lee,

Park,

Lee

et al. 2024

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…CRS can be classified into two subgroups, ECRS and non-ECRS, based on the number of eosinophils in the nasal polyps or mucosa, as one of the important phenotypes suggestive of type II inflammation, which is likely to complain with more severe symptoms, higher potential for treatment resistance, and more frequent of disease recurrence. 6 , 7 The recognition of ECRS may inform physicians to make different treatment decisions and take different post-treatment clinical monitoring. For patients requiring surgical treatment, there are some differences in the recommended surgical interventions for ECRS versus non-ECRS.…”

Section: Introductionmentioning

confidence: 99%

Predictive modeling for eosinophilic chronic rhinosinusitis: Nomogram and four machine learning approaches

Xiong,

Chen,

Zhang

et al. 2024

iScience

View full text Add to dashboard Cite

“…About 10% of the world’s population is afflicted by the disease, resulting in reduced quality of life and productivity [2]. According to the results of endoscopic and sinus computed tomography examinations, CRS is usually divided into two main phenotypes [3], namely, CRS with nasal polyps (CRSwNP) [4] and CRS without nasal polyps (CRSsNP) [5]. CRSsNP is usually attributed to the mechanical obstruction of sinus drainage channels caused by secondary inflammation and infection [6].…”

Section: Introductionmentioning

confidence: 99%

A Decade of Pathogenesis Advances in Non-Type 2 Inflammatory Endotypes in Chronic Rhinosinusitis: 2012–2022

Cui,

Zhu,

Zhao

et al. 2023

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by localized inflammation of the upper airways. CRS includes two main phenotypes, namely, CRS with nasal polyps and CRS without nasal polyps. The phenotype-based classification method cannot reflect the pathological mechanism. The endotype-based classification method has been paid more and more attention by researchers. It is mainly divided into type 2 and non-type 2 endotypes. The mechanism driving the pathogenesis of non-type 2 inflammation is currently unknown. In this review, the PubMed and Web of Science databases were searched to conduct a critical analysis of representative literature works on the pathogenesis of non-type 2 inflammation in CRS published in the past decade. This review summarizes the latest evidence that may lead to the pathogenesis of non-type 2 inflammation. It is the main method that analyzing the pathogenesis from the perspective of immunology. Genomics and proteomics technique provide new approaches to the study of the pathogenesis. Due to differences in race, environment, geography, and living habits, there are differences in the occurrence of non-type 2 inflammation, which increase the difficulty of understanding the pathogenesis of non-type 2 inflammation in CRS. Studies have confirmed that non-type 2 endotype is more common in Asian patients. The emergence of overlap and unclassified endotypes has promoted the study of heterogeneity in CRS. In addition, as the source of inflammatory cells and the initiation site of the inflammatory response, microvessels and microlymphatic vessels in the nasal mucosal subepithelial tissue participate in the inflammatory response and tissue remodeling. It is uncertain whether CRS patients affect the risk of infection with SARS-CoV-2. In addition, the pathophysiological mechanism of non-type 2 CRS combined with COVID-19 remains to be further studied, and it is worth considering how to select the befitting biologics for CRS patients with non-type 2 inflammation.

show abstract

A Decade of Clinical Advances in Chronic Rhinosinusitis: 2012–2022

Cited by 10 publications

References 105 publications

National Trends in Allergic Rhinitis and Chronic Rhinosinusitis and COVID-19 Pandemic-Related Factors in South Korea, from 1998 to 2021

National Trends in Allergic Rhinitis and Chronic Rhinosinusitis and COVID-19 Pandemic-Related Factors in South Korea, from 1998 to 2021

Predictive modeling for eosinophilic chronic rhinosinusitis: Nomogram and four machine learning approaches

A Decade of Pathogenesis Advances in Non-Type 2 Inflammatory Endotypes in Chronic Rhinosinusitis: 2012–2022

Contact Info

Product

Resources

About